Seastar medical holding corp ICU.US 總覽分析
ICU 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分低，若以價值投資為目標且有長期投資部位，需要嚴格執行自己的出場計畫來減持部位
ICU 近期報酬表現
0.40%
Seastar medical holding corp
0.38%
同產業平均
-0.07%
S&P500
與 ICU 同產業的標的表現
- IRIX Iridex corp價值 3 分趨勢 3 分波段 2 分籌碼 -股利 1 分查看更多
ICU 公司資訊
SeaStar Medical Holding Corporation is a commercial-stage medical technology company, which is focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The Company's Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient's body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).